Emerald Advisers LLC Has $36.59 Million Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Emerald Advisers LLC lowered its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 0.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 438,066 shares of the biopharmaceutical company's stock after selling 3,230 shares during the quarter. Intra-Cellular Therapies makes up approximately 1.4% of Emerald Advisers LLC's investment portfolio, making the stock its 15th largest position. Emerald Advisers LLC owned 0.41% of Intra-Cellular Therapies worth $36,587,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. True Wealth Design LLC acquired a new position in Intra-Cellular Therapies during the 3rd quarter worth approximately $32,000. GAMMA Investing LLC lifted its stake in shares of Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock valued at $63,000 after acquiring an additional 240 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Intra-Cellular Therapies during the 4th quarter valued at $96,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Intra-Cellular Therapies during the 3rd quarter valued at $97,000. Finally, Quarry LP grew its position in Intra-Cellular Therapies by 260.0% during the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock worth $132,000 after acquiring an additional 1,300 shares during the last quarter. Institutional investors own 92.33% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on ITCI shares. Mizuho downgraded Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and dropped their target price for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Piper Sandler reissued a "neutral" rating and set a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and raised their price target for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Finally, Royal Bank of Canada reissued a "sector perform" rating and issued a $132.00 price objective (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Ten research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Intra-Cellular Therapies presently has a consensus rating of "Hold" and an average target price of $106.08.

Remove Ads

Intra-Cellular Therapies Stock Up 0.0 %

ITCI traded up $0.06 during trading on Thursday, reaching $131.75. 1,866,089 shares of the stock traded hands, compared to its average volume of 1,346,632. The stock's 50-day moving average is $129.00 and its 200 day moving average is $99.05. Intra-Cellular Therapies, Inc. has a 12 month low of $64.09 and a 12 month high of $131.83. The stock has a market capitalization of $14.01 billion, a PE ratio of -151.44 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The business had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, equities research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.